San Diego’s Beacon Discovery formed a multi-year drug discovery collaboration with Takeda Pharmaceutical Company centered on gastrointestinal disorders.
Beacon will leverage its drug discovery experience in G-protein coupled receptors to identify gastrointestinal disorders with significant unmet medical need.
The agreement grants Japanese-based Takeda worldwide rights to develop, manufacture and commercialize products stemming from the collaboration. In exchange, Beacon will receive an undisclosed upfront payment, research support, and is eligible to receive milestone payments as well as royalties on future sales of products.
In addition to Takeda, Beacon has established partnerships with Boehringer Ingelheim, Janssen, and startups.